Navigation Links
Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Date:3/8/2011

CRANBURY, N.J., March 8, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND).  AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.  Based on data provided by Amicus, the FDA agreed with the Company's proposal to resume clinical development of AT2220, starting with a new Phase 2 study designed to evaluate the use of AT2220 when co-administered with enzyme replacement therapy (ERT) in subjects with Pompe disease.  The Company expects to commence this study in the first half of 2011 and to report preliminary results in the second half of 2011.

Co-administration of Pharmacological Chaperones with ERTAmicus previously reported promising preclinical data demonstrating that the co-administration of a pharmacological chaperone with ERT has the potential to address key limitations of ERT. The addition of a pharmacological chaperone has been shown to prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction in multiple disease-relevant tissues. Preclinical proof of concept has been established for Fabry disease and Pompe disease.

About AT2220Data from Phase 1 studies in 72 healthy volunteers demonstrated that AT2220 was generally safe and well tolerated at all doses evaluated with no drug-related serious adverse events. Based on these data and encouraging safety data from preclinical studies, Amicus initiated a Phase 2 clinical trial of AT2220 as a monotherapy treatment in adults with Pompe disease.  The protocol involved initial treatment with a high dose of AT2220.  Two patients enrolled in the trial experienced adverse events categorized as serious and probably related to treat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
2. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
5. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
6. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
9. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
10. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
11. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... ARBOR, Mich., May 14, 2012  Synthetic Biologics, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... Senior Vice President of Clinical & Regulatory Affairs. In ... design and implementation of all aspects of clinical development, ...
... 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ) ... months ended March 31, 2012 during the morning of Tuesday, ... conference call for investors later that day at 3:30 p.m. ... month periods.  Those interested in participating should call (800) 676-3536. ...
Cached Medicine Technology:Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 2Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 3
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... teens, TOPEKA, Kan., Oct. 19 Attorney General ... with new 30-second,radio public service announcements set to air ... coincide with the busy fall season and will,air more ... November. "With teens heading off to parties, dances ...
... recent study by Celent, a leading,financial services technology research ... of eight firms leading the way as a change ... transactions. Celent,s Healthcare Banking research service based its ... Mellon,s Treasury Services division to,apply its scale, technology and ...
... SPRINGS, Colo., Oct. 19 ,Spectranetics Corporation (Nasdaq: ... 2007 third quarter financial results prior to market ... host an,investment-community conference call beginning at 9:00 a.m. ... 31 to discuss those results,and to answer questions. ...
... SANTA ANA, Calif., Oct. 19 Today, Integrated,Healthcare ... owner of,four Orange County hospitals, announced that effective ... of all of its debt instruments. The,Company said ... with Medical,Capital Corporation and affiliates of Anaheim, California, ...
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... on Thursday, November 1, 2007 at,approximately 8:00 a.m. (ET). ... (ET) hosted by Joseph C. Papa, Perrigo,s President and ... live via webcast to interested,parties on the Perrigo website ...
... AAFP President Michael Fleming, MD will serve as Digital,s Medical ... Director ... Healthcare, a Wake,Forest, NC company specializing in retinal risk assessment for ... for Primary Care. In his new role, Dr. Fleming will,provide Digital ...
Cached Medicine News:Health News:Morrison Takes Aim at Underage Drinking in New Radio Campaign 2Health News:The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing 2Health News:Spectranetics to Hold 2007 Third Quarter Financial Results Conference Call on October 31 2Health News:IHHI Announces Completion of Re-Financing 2Health News:Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director 2
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
... includes bed side and near patient testing ... This growth has posed unique problems for ... and quality responsibility to decentralized areas focused ... Compounding the problem is the reality of ...
... First Consolidated Workstation to Automate Deparaffinization, ... Staining,Now you can perform deparaffinization, pretreatment, ... routine slide washing with a single ... preprogrammed Vysis protocols for fluorescence in ...
... sample preparation platform is an efficient system ... from patient samples using novel magnetic particle ... sample preparation and is cabable of processing ... a 1 ml sample volume., ,This platform ...
Medicine Products: